Substance / Medication

Milnacipran

Overview

Active Ingredient
milnacipran
RxNorm CUI
588250

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
0
Recruiting
12
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Levomilnacipran: More of the Same?
Gautam Mohan, Kaur Madhupreet, Jagtap Pranav et al. · Prim Care Companion CNS Disord · 2019
PMID: 31509357Meta-Analysis
Milnacipran for neuropathic pain in adults.
Derry Sheena, Phillips Tudor, Moore R Andrew et al. · Cochrane Database Syst Rev · 2015
PMID: 26148202Meta-AnalysisFull text (PMC)
Milnacipran for pain in fibromyalgia in adults.
Cording Malene, Derry Sheena, Phillips Tudor et al. · Cochrane Database Syst Rev · 2015
PMID: 26482422Meta-AnalysisFull text (PMC)
Milnacipran for neuropathic pain and fibromyalgia in adults.
Derry Sheena, Gill Dipender, Phillips Tudor et al. · Cochrane Database Syst Rev · 2012
PMID: 22419330Meta-AnalysisFull text (PMC)
Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.
Häuser Winfried, Petzke Frank, Üçeyler Nurcan et al. · Rheumatology (Oxford) · 2011
PMID: 21078630Meta-Analysis
Milnacipran versus other antidepressive agents for depression.
Nakagawa Atsuo, Watanabe Norio, Omori Ichiro M et al. · Cochrane Database Syst Rev · 2009
PMID: 19588396Meta-AnalysisFull text (PMC)
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range.
Nikolitch Katerina, Phillips Jennifer L, Daniels Stephen et al. · J Clin Psychiatry · 2025
PMID: 40875503RCT
Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
Radecki Daniel T, Robieson Weining Z, Gopalkrishnan Mallika et al. · J Child Adolesc Psychopharmacol · 2024
PMID: 38700708RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Milnacipran (substance)
SNOMED CT
441641002
UMLS CUI
C1533126
RxNorm CUI
588250

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.